Physician profile
Agnes A Solon
NPI 1558362004
$122,730.15
in general payments reported to CMS, 2019-2025
35 companies · $16K in 2025
The $16K reported for 2025 was more than what 92% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $5,772 · 2021: $2,607 · 2022: $17K · 2023: $19K · 2024: $19K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Travel and Lodging: $4,828 · Food and Beverage: $4,577 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,650.00 |
| Travel and Lodging | $4,827.61 |
| Food and Beverage | $4,576.61 |
| Education | $203.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $116,514.79 | 2019-2025 | Otezla, Evenity, Otezla |
| Abbvie INC. | $1,301.47 | 2020-2025 | Rinvoq, Humira |
| Ucb, INC. | $716.77 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $578.49 | 2019-2025 | |
| Janssen Biotech, INC. | $532.01 | 2020-2025 | Tremfya |
| Lilly USA, LLC | $503.60 | 2019-2023 | Taltz |
| Novartis Pharmaceuticals Corporation | $442.95 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $402.63 | 2022-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $281.15 | 2019-2025 | Benlysta |
| Genentech USA, INC. | $162.72 | 2019-2025 | Gazyva, Actemra |
| Genzyme Corporation | $156.64 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $153.69 | 2019 | |
| Medexus Pharma, INC. | $120.44 | 2019 | |
| Radius Health, INC. | $112.08 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $111.90 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $84.44 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $65.84 | 2022-2025 | Breztri, Farxiga |
| Celgene Corporation | $53.75 | 2019 | |
| Mallinckrodt Hospital Products INC. | $49.92 | 2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $44.29 | 2024-2025 | Rexulti |
| Sandoz INC. | $39.49 | 2023-2025 | Hyrimoz |
| Jazz Pharmaceuticals INC. | $36.67 | 2021 | |
| Sanofi-Aventis U.S. LLC | $33.84 | 2019-2021 | |
| Zyla Life Sciences, INC. | $28.34 | 2019 | |
| Alexion Pharmaceuticals, INC. | $27.62 | 2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.28 | 2023-2024 | Cyltezo |
| Ultragenyx Pharmaceutical INC. | $21.44 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.53 | 2021 | |
| Axsome Therapeutics, INC. | $18.21 | 2025 | Auvelity |
| Theratechnologies INC. | $18.07 | 2021 | |
| Novo Nordisk INC | $16.49 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $15.91 | 2022 | |
| Sanofi Pasteur INC. | $13.61 | 2025 | |
| Eisai INC. | $12.51 | 2022 | |
| Horizon Therapeutics Plc | $11.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Agnes Solon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.